Karyopharm y Menarini Group reciben una opinión positiva del CHMP con respecto a NEXPOVIO® (selinexor) para el tratamiento de pacientes con mieloma múltiple refractario ...Middle East

-- Se prevé la decisión de la Comisión Europea en un plazo aproximado de 60 días -- NEWTON, Massachusetts, y FLORENCIA, Italia, 22 de mayo de 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), una empresa farmacéutica en etapa comercial pionera en nuevas terapias contra el...

Hence then, the article about karyopharm y menarini group reciben una opinion positiva del chmp con respecto a nexpovio selinexor para el tratamiento de pacientes con mieloma multiple refractario was published today ( Sunday 22/05/2022 - 04:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Karyopharm y Menarini Group reciben una opinión positiva del CHMP con respecto a NEXPOVIO® (selinexor) para el tratamiento de pacientes con mieloma múltiple refractario )

Also on site :

• ESMO 2026 .. Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
• I worked with Trump. I know why he is being so easily goaded into a forever war
• On Sebastia’s hilltop, Israelis and Palestinians are fighting over who owns the past and controls the present